Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16882160 | 0.86 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL18249758 | 0.85 | DGAT2 (0.41) | SMN1; SMN2ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL20239277 | 0.82 | GRM5 (0.45) | SMN1; SMN2ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL20239233 | 0.75 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL20239207 | 0.74 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL18153300 | 0.73 | MEN1 (0.51) | SMN1; SMN2ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL16738665 | 0.73 | DGAT2 (0.44) | SMN1; SMN2ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL18951960 | 0.73 | MEN1 (0.50) | SMN1; SMN2ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL18249751 | 0.72 | PGR (0.54) | SMN1; SMN2ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL16738664 | 0.72 | PDE2A (0.41) | SMN1; SMN2ALDH1A1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107635975-B | DGAT2 inhibitors | 伊莱利利公司 | 2020-07-24 | — | — | CN | disclosed |
| EP-3298001-B1 | DGAT2 INHIBITORS | LILLY CO ELI (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10053429-B2 | DGAT2 inhibitors | ELI LILLY AND COMPANY (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
| EP-3298001-A1 | NOVEL DGAT2 INHIBITORS | Eli Lilly and Company (US) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016187384-A1 | NOVEL DGAT2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | DGAT2, DGAT1, LCAT | SMN1; SMN2 4828/4885ALDH1A1 1430/4885RAB9A 1170/4885 |
| US-10053429-B2 | DGAT2 inhibitors | DGAT2, DGAT1, LCAT | SMN1; SMN2 4835/4885ALDH1A1 1189/4885RAB9A 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.